Amgen, Teva to face Sensipar monopoly claims

03-12-2020

Rory O'Neill

Amgen, Teva to face Sensipar monopoly claims

Grand Warszawski / Shutterstock.com

Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar (cinacalcet) off the market.


Teva, Amgen, Sensipar, reverse payment, antitrust, competition, pay-for-delay, Delaware

LSIPR